Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
E125307-1mg | 1mg | In stock | $16.90 | |
E125307-5mg | 5mg | In stock | $68.90 | |
E125307-10mg | 10mg | In stock | $98.90 | |
E125307-25mg | 25mg | In stock | $206.90 | |
E125307-50mg | 50mg | In stock | $355.90 |
Synonyms | pinometostat|1380288-87-8|EPZ-5676|EPZ5676|Pinometostat, trans-|Pinometostat [INN]|Pinometostat anhydrous|Pinometostat(EPZ5676)|(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) |
---|---|
Specifications & Purity | ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Dry ice |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of DOT1 like histone lysine methyltransferase |
Product Description | Pinometostat (EPZ5676) is an S-adenosyl methionine (SAM) competitive inhibitor of protein methyltransferase DOT1L with Ki of 80 pM in a cell-free assay, demonstrating >37,000-fold selectivity against all other PMTs tested, inhibits H3K79 methylation in tumor. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 488201822 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488201822 |
IUPAC Name | (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[[3-[2-(6-tert-butyl-1H-benzimidazol-2-yl)ethyl]cyclobutyl]-propan-2-ylamino]methyl]oxolane-3,4-diol |
INCHI | InChI=1S/C30H42N8O3/c1-16(2)37(13-22-25(39)26(40)29(41-22)38-15-34-24-27(31)32-14-33-28(24)38)19-10-17(11-19)6-9-23-35-20-8-7-18(30(3,4)5)12-21(20)36-23/h7-8,12,14-17,19,22,25-26,29,39-40H,6,9-11,13H2,1-5H3,(H,35,36)(H2,31,32,33)/t17?,19?,22-,25-,26-,29-/m1/s1 |
InChi Key | LXFOLMYKSYSZQS-XKHGBIBOSA-N |
Canonical SMILES | CC(C)N(CC1C(C(C(O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C |
Isomeric SMILES | CC(C)N(C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O)C4CC(C4)CCC5=NC6=C(N5)C=C(C=C6)C(C)(C)C |
PubChem CID | 57345410 |
Molecular Weight | 562.71 |
CAS Registry No. | 1380288-87-8 |
---|---|
ChEMBL Ligand | CHEMBL3087499 |
PubChem CID | 57345410 |
RCSB PDB Ligand | EP6 |
PubChem SID | 488201822 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
C23311055 | Certificate of Analysis | Jan 16, 2023 | E125307 |
C2331470 | Certificate of Analysis | Jan 16, 2023 | E125307 |
C2331521 | Certificate of Analysis | Jan 16, 2023 | E125307 |
C2331523 | Certificate of Analysis | Jan 16, 2023 | E125307 |
C2331548 | Certificate of Analysis | Jan 16, 2023 | E125307 |
C2331549 | Certificate of Analysis | Jan 16, 2023 | E125307 |
C2331550 | Certificate of Analysis | Jan 16, 2023 | E125307 |
C2331551 | Certificate of Analysis | Jan 16, 2023 | E125307 |
C2331552 | Certificate of Analysis | Jan 16, 2023 | E125307 |
C2331553 | Certificate of Analysis | Jan 16, 2023 | E125307 |
Solubility | ≥28.15 mg/mL in DMSO; insoluble in H2O; ≥50.3 mg/mL in EtOH with ultrasonic |
---|
1. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, Allain CJ, Klaus CR, Raimondi A, Scott MP et al.. (2013) Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.. Blood, 122 (6): (1017-25). [PMID:23801631] |
2. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L et al.. (2011) MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.. Cancer Cell, 20 (1): (66-78). [PMID:21741597] |
3. Muntean AG, Hess JL. (2012) The pathogenesis of mixed-lineage leukemia.. Annu Rev Pathol, 7 (3): (283-301). [PMID:22017583] |